REGN7508

Phase 3Small molecule

Regeneron

REGN7508 is one of 113 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

112

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

Total Knee ArthroplastyActive, not recruiting

Atrial FibrillationActive, not recruiting

Peripheral Artery DiseaseActive, not recruiting

Atrial Fibrillation (AF)Recruiting

Symptomatic Venous Thromboembolism (VTE)Recruiting

Venous Thromboembolism (VTE)Not yet recruiting

Peripheral Artery Disease (PAD)Recruiting

Venous ThromboembolismPhase 3

Active, not recruiting

Total Knee ArthroplastyPhase 3

Active, not recruiting

Atrial FibrillationPhase 2

Active, not recruiting

Peripheral Artery DiseasePhase 3

Active, not recruiting

Atrial Fibrillation (AF)Phase 3

Recruiting

Symptomatic Venous Thromboembolism (VTE)Phase 3

Recruiting

Venous Thromboembolism (VTE)Phase 3

Not yet recruiting

Peripheral Artery Disease (PAD)Phase 3

Recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

REGN7508

Regeneron

Phase 3

12 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Calan

4 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 10

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Atrial Fibrillation (AF)

NCT07175428

Phase 3Recruiting

Venous Thromboembolism (VTE)

NCT07015905

Q3 2027

Phase 3Recruiting

Symptomatic Venous Thromboembolism (VTE)

NCT07213778

Q2 2029

Phase 3Recruiting

Atrial Fibrillation (AF)

NCT07430956

Q3 2029

Phase 3Not yet recruiting

Venous Thromboembolism (VTE)

NCT07697599

Clinical

Trials by Indication[1]

Venous Thromboembolism (VTE)2 trials

A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07015905·2,000 enrolled

A Master Protocol for a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, for Prophylaxis of Venous Thromboembolism in Participants With a Peripherally Inserted Central Catheter (PICC) (ROXI-PEAK)

Not yet recruiting· Regeneron logo

Regeneron·Phase 3·NCT07697599·1,908 enrolled

Atrial Fibrillation (AF)2 trials

A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT07175428·1,200 enrolled

A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, Versus Placebo in Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07430956·2,628 enrolled

Intravenous1 trial

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Completed· Regeneron logo

Regeneron·Phase 1·NCT05603195·80 enrolled

Catheter1 trial

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06299111·195 enrolled

Prevention1 trial

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07410117·860 enrolled

5 more indications

Adult1 trial

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

Completed· Regeneron logo

Regeneron·Phase 2·NCT06454630·179 enrolled

Venous Thromboembolism1 trial

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Not yet recruiting· Regeneron logo

Regeneron·Phase 3·NCT07493304·1,600 enrolled

Gastrointestinal1 trial

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Completed· Regeneron logo

Regeneron·Phase 1·NCT06444178·224 enrolled

Peripheral Artery Disease (PAD)1 trial

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants With Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07318610·7,050 enrolled

Symptomatic Venous Thromboembolism (VTE)1 trial

A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07213778·2,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for REGN7508. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN7508 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN7508. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Regeneron

REGN7508

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q2 2029

Q3 2029

Trials by Indication[1]

Venous Thromboembolism (VTE)2 trials

Atrial Fibrillation (AF)2 trials

Intravenous1 trial

Catheter1 trial

Prevention1 trial

Adult1 trial

Venous Thromboembolism1 trial

Gastrointestinal1 trial

Peripheral Artery Disease (PAD)1 trial

Symptomatic Venous Thromboembolism (VTE)1 trial

References

Drug Info

Quick Facts

Related News